Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Proc Natl Acad Sci U S A 2000 Jul;97(14):8015-20

Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA 19104-6144, USA.

Emerging evidence suggests that transforming growth factor-beta (TGF-beta) is an important mediator of diabetic nephropathy. We showed previously that short-term treatment with a neutralizing monoclonal anti-TGF-beta antibody (alphaT) in streptozotocin-diabetic mice prevents early changes of renal hypertrophy and increased matrix mRNA. To establish that overactivity of the renal TGF-beta system mediates the functional and structural changes of the more advanced stages of nephropathy, we tested whether chronic administration of alphaT prevents renal insufficiency and glomerulosclerosis in the db/db mouse, a model of type 2 diabetes that develops overt nephropathy. Diabetic db/db mice and nondiabetic db/m littermates were treated intraperitoneally with alphaT or control IgG, 300 microgram three times per week for 8 wk. Treatment with alphaT, but not with IgG, significantly decreased the plasma TGF-beta1 concentration without decreasing the plasma glucose concentration. The IgG-treated db/db mice developed albuminuria, renal insufficiency, and glomerular mesangial matrix expansion associated with increased renal mRNAs encoding alpha1(IV) collagen and fibronectin. On the other hand, treatment with alphaT completely prevented the increase in plasma creatinine concentration, the decrease in urinary creatinine clearance, and the expansion of mesangial matrix in db/db mice. The increase in renal matrix mRNAs was substantially attenuated, but the excretion of urinary albumin factored for creatinine clearance was not significantly affected by alphaT treatment. We conclude that chronic inhibition of the biologic actions of TGF-beta with a neutralizing monoclonal antibody in db/db mice prevents the glomerulosclerosis and renal insufficiency resulting from type 2 diabetes.

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.120055097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC16662PMC
July 2000

Publication Analysis

Top Keywords

db/db mice
16
renal insufficiency
16
mesangial matrix
12
mice prevents
8
matrix expansion
8
treatment alphat
8
antibody db/db
8
creatinine clearance
8
growth factor-beta
8
type diabetes
8
glomerular mesangial
8
neutralizing monoclonal
8
renal
8
db/db
6
matrix
6
alphat
6
mice
6
treatment
5
mice developed
4
week treatment
4

Altmetric Statistics

References

(Supplied by CrossRef)

Ziyadeh et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993

Ziyadeh et al.
Kidney international. Supplement 1996

Ziyadeh et al.
Mineral and electrolyte metabolism 1995

American Journal of Physiology -- Legacy Content 1991

Danne et al.
Diabetes 1993

Haneda et al.
Diabetologia 1991

Ziyadeh et al.
Journal of Clinical Investigation 1994

Bleyer et al.
Kidney international 1994

Goldfarb et al.
Diabetes 1991

Studer et al.
Diabetes 1993

American Journal of Physiology -- Legacy Content 1994

Similar Publications